Evanson Asset Management LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 0.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,475 shares of the medical research company’s stock after selling 1 shares during the period. Evanson Asset Management LLC’s holdings in Amgen were worth $254,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Camelot Portfolios LLC acquired a new position in Amgen in the first quarter worth about $1,429,000. Shelton Capital Management grew its stake in Amgen by 82.7% in the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares in the last quarter. Cadence Bank NA grew its stake in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after purchasing an additional 197 shares in the last quarter. Telos Capital Management Inc. grew its stake in Amgen by 1.6% in the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after purchasing an additional 227 shares in the last quarter. Finally, Palladium Partners LLC grew its stake in Amgen by 1.9% in the first quarter. Palladium Partners LLC now owns 112,042 shares of the medical research company’s stock worth $18,382,000 after purchasing an additional 2,079 shares in the last quarter. Institutional investors and hedge funds own 78.09% of the company’s stock.

A number of equities analysts recently commented on AMGN shares. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research note on Tuesday, June 13th. Mizuho reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research note on Sunday, July 9th. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research note on Tuesday, July 11th. Finally, Cann reiterated a “buy” rating and issued a $203.00 price target (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $186.14.

Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.23% during midday trading on Thursday, reaching $187.74. The company had a trading volume of 755,475 shares. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The firm’s 50 day moving average price is $175.99 and its 200-day moving average price is $169.31. The company has a market capitalization of $136.99 billion, a P/E ratio of 17.10 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the business earned $2.84 earnings per share. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.44%. Amgen’s payout ratio is 41.93%.

ILLEGAL ACTIVITY NOTICE: “Evanson Asset Management LLC Decreases Position in Amgen Inc. (AMGN)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/21/evanson-asset-management-llc-decreases-position-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.